Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Original Article

R.K. Murthy, S. Loi, A. Okines, E. Paplomata, E. Hamilton, S.A. Hurvitz, N.U. Lin, V. Borges, V. Abramson, C. Anders, P.L. Bedard, M. Oliveira, E. Jakobsen, T. Bachelot, S.S. Shachar, V. Müller, S. Braga, F.P. Duhoux, R. Greil, D. Cameron, L.A. Carey, G. Curigliano, K. Gelmon, G. Hortobagyi, I. Krop, S. Loibl, M. Pegram, D. Slamon, M.C. Palanca-Wessels, L. Walker, W. Feng, and E.P. Winer

N Engl J Med 2020;382:597-609

Course summary

Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
02/12/2020
Course expires: 
02/13/2022

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Course closed

This course closed on Sunday, February 13, 2022 - 11:59pm.